{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:48:21Z","timestamp":1784958501469,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Epidermal necrolysis, the unifying term for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), is a severe cutaneous drug reaction associated with high morbidity and mortality. Given the rarity of this disease, large-scale prospective research studies are limited. Significant institutional and geographical variations in treatment practices highlight the need for standardization of clinical assessment scores and prioritization of research outcome measures in epidermal necrolysis. At the present, clinical assessment is typically simplified to total body surface area (BSA) involvement, with little focus on morphology. Validated clinical scoring systems are used as mortality prognostication tools, with SCORTEN being the best-validated tool thus far, although the ABCD-10 has also been recently introduced. These tools are imperfect in that they tend to either overestimate or underestimate mortality in certain populations and are not designed to monitor disease progression. Although mortality is often used as a primary endpoint for epidermal necrolysis studies, this outcome fails to capture more nuanced changes in skin disease such as arrest of disease progression while also lacking a validated skin-directed inclusion criterion to stratify patients based on the severity of skin disease at study entry. In addition to mortality, many studies also use BSA stabilization or time to re-epithelialization as endpoints, although these are not clearly defined morphologically, and inter- and intra-rater reliability are unclear. More specific, validated cutaneous assessment scores are necessary in order advance therapeutic options for epidermal necrolysis. In this review, we summarize the strengths and weaknesses of current clinical assessment practices in epidermal necrolysis and highlight the need for standardized research tools to monitor cutaneous involvement throughout the hospitalization.<\/jats:p>","DOI":"10.3389\/fmed.2022.883121","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:53:50Z","timestamp":1655376830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Allison S.","family":"Dobry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Himed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a pan-European multicenter study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","article-title":"Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Duplisea","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0484.","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis-coordinating research priorities to move the field forward","author":"Phillips","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1468-3083.2012.04502.x","article-title":"SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population","volume":"27","author":"Hu","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1111\/ijd.12466","article-title":"A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis","volume":"54","author":"Bansal","year":"2015","journal-title":"Int J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J Burn Care Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of mortality prognostication in patients with epidermal necrolysis: the role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)","volume":"158","author":"Koh","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2019.0998","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.burns.2017.09.015","article-title":"Improving mortality outcomes of Stevens Johnson syndrome\/toxic epidermal necrolysis: a regional burns centre experience","volume":"44","author":"Nizamoglu","year":"2018","journal-title":"Burns J Int Soc Burn Inj."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520494.","article-title":"Comparing the accuracy of ABCD-10 and SCORTEN in predicting the in-hospital mortality of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multi-institutional study from central China","author":"Suo","year":"2021","journal-title":"Dermatol Basel Switz."},{"key":"B17","unstructured":"NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome\/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Identifier NCT01696500 (2012\u20132014)"},{"key":"B18","unstructured":"A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis\n            KroshinskyD."},{"key":"B19","unstructured":"NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis\n            PhillipsEJ"},{"key":"B20","unstructured":"Evaluating the Effect of Isotretinoin in Regulatory T-Cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study\n            SaavedraAP"},{"key":"B21","unstructured":"Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis\n            RousseauA\n          28329382"},{"key":"B22","unstructured":"Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)\n            Ben SaidB"},{"key":"B23","unstructured":"Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial\n            OroS"},{"key":"B24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/s41433-020-01203-4","article-title":"Mucous membrane grafting (fibrin glue vs. suture) for lid margin pathologies in Stevens-Johnson syndrome: randomized comparative study","volume":"35","author":"Pushker","year":"2021","journal-title":"Eye."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","volume":"27","author":"Imahara","year":"2006","journal-title":"J Burn Care Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s004310050561","article-title":"Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children","volume":"156","author":"Kakourou","year":"1997","journal-title":"Eur J Pediatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2018.06.002","article-title":"Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"79","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.883121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:53:54Z","timestamp":1655376834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.883121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":34,"alternative-id":["10.3389\/fmed.2022.883121"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.883121","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"883121"}}